The Federal Trade Commission in the US is planning to sue the owners of the three largest pharmacy benefits managers (PBMs) for anti-competitive behaviour, on the heels of its damning repor
A long-awaited report from the US Federal Trade Commission (FTC) on pharmacy benefit managers (PBMs) is out – and will make uncomfortable reading for the pharma supply chain middlemen.
Shares in Teva Pharmaceutical have dipped sharply after reports that the Federal Trade Commission (FTC) has opened an investigation into the company focusing on improperly listed patents in
The US Federal Trade Commission (FTC) has expanded its campaign against so-called ‘junk’ patents intended to extend market exclusivity and block generic rivals.
It’s been a couple of months since pharma’s annual JP Morgan Chase Healthcare Conference, where the mood around pharma M&A this year was optimistic, albeit with a few caveats.
The Federal Trade Commission (FTC) is asking for information from wholesalers and other middlemen in the pharmaceutical supply chain in an investigation into worsening sho
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh